(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Gene therapy has expanded rapidly over the last decade. The number of clinical trials reported by 2001 included 532 protocols and 3436 patients. Phase I trials predominate with 359 trials of 1774 patients versus Phase II (57 trials with 507 patients) and Phase III (3 trials of 251 patients). The disease overwhelmingly targeted by gene therapy is cancer: involving 331 trials with 2361 patients. Despite the somewhat disappointing results of clinical trials to date, gene therapy offers tremendous promise for the future of cancer therapy. The area of gene therapy is vast, and both malignant and nonmalignant cells can be targeted. Suicide Gene Therapy: Methods and Reviews covers gene therapy that targets malignant cells in a treatment that has become known as "suicide gene therapy. " Basically, this approach uses the transduction of cancer cells with a gene for a foreign enzyme that, when expressed, is able to activate a nontoxic prodrug into a highly cytotoxic drug able to kill the cancer cell population. This is a major area in cancer gene therapy-in 2001 this technique was represented by 52 clinical protocols with a total of 567 patients. Additional trials used multiple gene therapy protocols that also involved suicide gene therapy (83 with 497 patients), indicating that the interest in this area is considerable. Suicide Gene Therapy: Methods and Reviews aims to cover comprehensively, both in theoretical and practical terms, the rapidly evolving area of suicide gene therapy for cancer.
Contents:
Introduction to the Background, Principles, and State of the Art in Suicide Gene Therapy
Ion Niculescu-Duvaz and Caroline J. Springer
Introduction to Vectors for Suicide Gene Therapy
Caroline J. Springer
Construction of VNP20009: A Novel, Genetically Stable Antibiotic-Sensitive Strain of Tumor-Targeting Salmonella for Parenteral Administration in Humans
Kenneth Brooks Low, Martina Ittensohn, Xiang Luo, Li-Mou Zheng, Ivan King, John M. Pawelek, and David Bermudes
Nonreplicating DNA Viral Vectors for Suicide Gene Therapy: The Adenoviral Vectors
Masato Yamamoto and David T. Curiel
Replication-Selective Oncolytic Adenoviruses
Gunnel Hallden, Stephen H. Thorne, Jingping Yang, and David H. Kirn
Retroviral Vectors for Suicide Gene Therapy
Colin Porter
Nonviral Liposomes
Andrew D. Miller
Peptide- and Polymer-Based Gene Delivery Vehicles
Richard Brokx and Jean Gariepy
Design of Prodrugs for Suicide Gene Therapy
Dan Niculescu-Duvaz, Ion Niculescu-Duvaz, and Caroline J. Springer
Cytochrome P450-Based Gene Therapies for Cancer
E. Antonio Chiocca and David J. Waxman
Tumor Sensitization to Purine Analogs by E. coli PNP
Kimberly V. Curlee, William B. Parker, and Eric J. Sorscher
Enzyme-Prodrug Systems: Carboxylesterase/CPT-11
Mary K. Danks and Philip M. Potter
Enzyme-Prodrug Systems: Thymidine Phosphorylase/5'-Deoxy-5-Fluorouridine
Alexandre Evrard, Joseph Ciccolini, Pierre Cuq, and Jean-Paul Cano
Methods to Improve Efficacy in Suicide Gene Therapy Approaches: Targeting Prodrug-Activating Enzymes Carboxypeptidase G2 and Nitroreductase to Different Subcellular Compartments
Silke Schepelmann, Robert Spooner, Frank Friedlos, and Richard Marais
Extracellular b-Glucuronidase for Gene-Directed Enzyme-Prodrug Therapy
Sabine Brusselbach
Enhancementof Suicide Gene Prodrug Activation by Random Mutagenesis
Jean-Emmanuel Kurtz and Margaret E. Black
Combination Suicide Gene Therapy
Wolfgang Uckert, Brian Salmons, Christian Beltinger, Walter H. Gunzburg, and Thomas Kammertoens
Immune Response to Suicide Gene Therapy
Shigeki Kuriyama, Hirohisa Tsujinoue, and Hitoshi Yoshiji
Targeting Cancer With Gene Therapy Using Hypoxia as a Stimulus
Gabi U. Dachs, Olga Greco, and Gillian M. Tozer
Radiation-Activated Antitumor Vectors
Simon D. Scott and Brian Marples
In Vitro and In Vivo Models for the Evaluation of GDEPT: Quantifying Bystander Killing in Cell Cultures and Tumors
William R. Wilson, Susan M. Pullen, Alison Hogg, Stephen M. Hobbs, Frederik B. Pruijn, and Kevin O. Hicks
Suicide Gene Therapy in Liver Tumors
Long R. Jiao, Roman Havlik, Joanna Nicholls, Steen Lindkaer Jensen, and Nagy A. Habib
Clinical Trials With GDEPT: Cytosine Deaminase and 5-Fluorocytosine
Nicola L. Brown and Nicholas R. Lemoine
The Nitroreductase/CB1954 Enzyme-Prodrug System
Nicola K. Green, David J. Kerr, Vivien Mautner, Peter A. Harris, and Peter F. Searle
Side Effects of Suicide Gene Therapy
Marjolijn M. van der Eb, Bertie de Leeuw, Alex J. van der Eb, and Rob C. Hoeben
Antibody-Directed Enzyme-Prodrug Therapy
R. Barbara Pedley, Surinder K. Sharma, Robert E. Hawkins, and Kerry A. Chester
Bioreductive Prodrugs for Cancer Therapy
Beatrice Seddon, Lloyd R. Kelland, and Paul Workman
Index
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: November, 2010
Pages: 572
Weight: 831g
Availability: Available
Subcategories: Oncology
From the same series
